Print
Email
Print Edition Stories
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Cambridge-based biotech Pervasis Therapeutics Inc. is claiming it has new data indicating its drug PVS-10200 can potentially help patients with peripheral arterial disease recover after angioplasty and stent placements.
Often, after such procedures, the patient faces restenosis — narrowing of the arteries — which can cause complications and can require further treatment. However, Pervasis says it has preclinical data around its new cell treatment demonstrating that it enhanced “vascular repair.”
Researchers evaluated the ultrasound-guided injection of PVS-10200 to the outside of pigs’ femoral arteries immediately following angioplasty and stent placement. According to a statement, Pervasis said PVS-10200 can regulate the inflammatory response in a blood vessel to permit natural healing and control restenosis. The company will now start a Phase 2 trial to further evaluate the safety and efficacy of PVS-10200.
Peripheral artery disease affects approximately eight million Americans, according to the American Heart Association. It involves the buildup of fatty deposits on the inner lining of the artery walls. People with it have four to five times higher risk of heart attack and stroke compared to those who don’t.
Privately held, five-year-old Pervasis focuses on creating cell-based compounds and devices. It is also exploring technology in non-vascular applications, such as bone and joint repair, wound healing and inflammation. Last October, Pervasis named Frederic Chereau president and CEO of the company. Chereau formerly served as vice president and general manager of Genzyme Cardiovascular, a business unit of Genzyme Corp.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
